Literature DB >> 26881715

An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.

Deepak Bhattarai, Sarbijt Singh, Yerin Jang, Seung Hyeon Han, Kyeong Lee1, Yongseok Choi2.   

Abstract

Increased investments and development of new technologies in drug discovery have barely improved the outcome of medicinal entities in the drug discovery market from a long time. Minimal success rates of drug approvals, poor safety profiles, and long development processes are some of many hurdles encountered in the drug discovery field. Therefore, drug repurposing can provide an alternative approach to meet the demands of the new, potent and safe anti-cancer agents in terms of both economic cost and time efficiency. The common molecular pathways of different diseases and secondary indications of most of the approved drugs, and advances in genomics, informatics and biology, as well as the availability of approved or safe drug libraries can certainly provide an improved and efficient way of screening safer drugs for new indications. Promising results of drug repurposing in different therapeutic areas have encouraged the scientific community to discover new drugs for different diseases using this methodology. Herein, we provide a general overview of structurally and functionally diverse approved drugs that have been repurposed as anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26881715     DOI: 10.2174/1568026616666160216153618

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  9 in total

Review 1.  Opportunities for Host-targeted Therapies for Malaria.

Authors:  Elizabeth K K Glennon; Selasi Dankwa; Joseph D Smith; Alexis Kaushansky
Journal:  Trends Parasitol       Date:  2018-08-16

2.  Report from the 36th Annual Meeting of the Korean Society of Gynecologic Oncology (KSGO).

Authors:  Ju Hyun Kim; Joseph J Noh; Kyung Jin Eoh; Young Tae Kim
Journal:  J Gynecol Oncol       Date:  2021-07       Impact factor: 4.401

3.  Clinical trials to assess adjuvant therapeutics for severe malaria.

Authors:  Rosauro Varo; Clara Erice; Sydney Johnson; Quique Bassat; Kevin C Kain
Journal:  Malar J       Date:  2020-07-24       Impact factor: 2.979

4.  Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.

Authors:  Xin Wang; Xingye Wu; Zhonglin Zhang; Chao Ma; Tingting Wu; Shengli Tang; Zongyue Zeng; Shifeng Huang; Cheng Gong; Chengfu Yuan; Linghuan Zhang; Yixiao Feng; Bo Huang; Wei Liu; Bo Zhang; Yi Shen; Wenping Luo; Xi Wang; Bo Liu; Yan Lei; Zhenyu Ye; Ling Zhao; Daigui Cao; Lijuan Yang; Xian Chen; Rex C Haydon; Hue H Luu; Bing Peng; Xubao Liu; Tong-Chuan He
Journal:  Sci Rep       Date:  2018-12-17       Impact factor: 4.379

5.  Repurposing Dihydropyridines for Treatment of Helicobacter pylori Infection.

Authors:  Andrés González; Javier Casado; Eduardo Chueca; Sandra Salillas; Adrián Velázquez-Campoy; Vladimir Espinosa Angarica; Lucie Bénejat; Jérome Guignard; Alban Giese; Javier Sancho; Philippe Lehours; Ángel Lanas
Journal:  Pharmaceutics       Date:  2019-12-15       Impact factor: 6.321

Review 6.  Drug Repositioning for Effective Prostate Cancer Treatment.

Authors:  Beste Turanli; Morten Grøtli; Jan Boren; Jens Nielsen; Mathias Uhlen; Kazim Y Arga; Adil Mardinoglu
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566

7.  Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Yohan Suryo Rahmanto; Kouji Banno; Yu Yu; Yusuke Matoba; Keiko Watanabe; Moito Iijima; Takashi Takeda; Haruko Kunitomi; Miho Iida; Masataka Adachi; Kanako Nakamura; Kosuke Tsuji; Kenta Masuda; Hiroyuki Nomura; Eiichiro Tominaga; Daisuke Aoki
Journal:  Oncotarget       Date:  2017-08-07

8.  Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis.

Authors:  Jones Gyamfi; Yun-Hee Lee; Byung Soh Min; Junjeong Choi
Journal:  Sci Rep       Date:  2019-08-05       Impact factor: 4.379

9.  Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer.

Authors:  Geertje van der Horst; Arjanneke F van de Merbel; Eline Ruigrok; Maaike H van der Mark; Emily Ploeg; Laura Appelman; Siri Tvingsholm; Marja Jäätelä; Janneke van Uhm; Marianna Kruithof-de Julio; George N Thalmann; Rob C M Pelger; Chris H Bangma; Joost L Boormans; Gabri van der Pluijm; Ellen C Zwarthoff
Journal:  Mol Oncol       Date:  2020-10-16       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.